Lower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THC

Loading...
Loading...
  • Anebulo Pharmaceuticals Inc ANEB has announced interim data from the first two cohorts of Part B of its ongoing Phase 2 trial of ANEB-001 for acute cannabinoid intoxication (ACI).
  • Subjects challenged with a higher 21 mg oral THC dose and treated with a placebo showed greater central nervous system (CNS) effects than observed in Part A with 10.5 mg THC. 
  • The effects included a substantial increase in feeling high and body sway, decreased alertness, and slightly increased heart rate.
  • Subjects treated with 10 mg or 30 mg ANEB-001 led to significant and sustained reductions in the visual analog scale (VAS) feeling high score, improvement in the VAS alertness scale and a reduction in THC-induced body sway compared to placebo.
  • 100% of subjects given 21 mg THC with placebo met the VAS threshold for feeling high compared to only one subject per group treated with ANEB-001 at 10 mg or 30 mg doses. 
  • Although the THC-induced increase in heart rate in this study was small, there was a trend towards improvement with ANEB-001 compared to placebo. 
  • The 10 mg and 30 mg ANEB-001 doses had similar effects to previous higher doses used in Part A, despite doubling the THC dose. 
  • Anebulo also announced a private placement of 2.26 million shares and accompanying warrants to purchase up to 2.26 million for $2.935. 
  • The warrants have an exercise price of $4.215 per share.
  • In July, Anebulo announced positive topline data from the trial's Part A.
  • Price Action: ANEB shares closed at $2.81 on Friday.
Loading...
Loading...
Posted In: NewsPenny StocksHealth CareOfferingsGeneralBriefs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...